# Copper Peptide Hair Growth Research — GHK-Cu Follicle Studies > Copper Peptide Hair Growth Research on GHK-Cu: the 45-patient androgenetic-alopecia trial (+71.5 hairs vs +9.6 placebo), C3H-mouse follicle stimulation, the VEGF angiogenesis mechanism, and a non-androgenic mode of action. Cited. The controlled human signal, the founding mouse study, and the angiogenic mechanism — read for exactly what each one demonstrates and where the evidence stops. ## The controlled human signal in copper peptide hair growth research Copper Peptide Hair Growth Research on GHK-Cu has one controlled human anchor, and it is worth stating precisely. In a 6-month trial of 45 men with androgenetic alopecia (Norwood-Hamilton II-V), a topical complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide (ALAVAX) increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, versus 9.6 for placebo (p<0.05), with no adverse events in any group [4]. That is the strongest controlled efficacy signal for a GHK-containing topical in the published record. The honest qualifier is in the formulation: ALAVAX is a 5-ALA plus GHK combination, not pure GHK-Cu. The hair-count gain is real and placebo-controlled, but it belongs to the combination product. A 2026 review of short peptides for hair loss treats this 45-patient trial as foundational peptide hair-loss evidence while attributing the mechanism to GHK-Cu's effect on VEGF, angiogenesis and follicular matrix turnover [5]. The preclinical groundwork is older still: peptide-copper complexes stimulated hair-follicle activity and growth in C3H mice, the early animal-model basis for copper peptides in hair research [9]. Notice also the dose-response oddity worth flagging: the lower 50 mg/mL concentration produced the larger hair-count gain (71.5 versus 52.6 at 100 mg/mL) [4]. That kind of non-monotonic response is not unusual for signaling peptides, where higher is not always better, but it underlines that the field has not yet established an optimal concentration even within its single controlled trial. The result is genuine and the direction is clear; the precise dosing is not settled. ## The angiogenic mechanism behind the hair data What ties the human trial, the mouse study and the reviews together is a single proposed mechanism: angiogenesis. A 2026 short-peptide review reports GHK-Cu increases VEGF production in dermal fibroblasts, stimulates microvascular angiogenesis, and promotes follicular extracellular-matrix turnover [5]. A hair follicle is a metabolically demanding organ that depends on its surrounding microvasculature; improving the blood supply and rebuilding the perifollicular matrix is a plausible route to extended anagen (the active growth phase) without touching the hormonal axis. The dermal-papilla cells at the base of the follicle are the likely target — copper-peptide research reports promotion of their proliferation and inhibition of their apoptosis in study models, alongside Wnt/beta-catenin activation associated with anagen entry [6]. None of this requires the follicle-shrinking hormone pathway that androgenetic alopecia is named for, which is exactly why the mechanism is described as complementary to, not a replacement for, hormonal approaches in the literature. ## Does copper peptide regrow hair? In the 45-patient ALAVAX trial, hair count rose by 52.6 (100 mg/mL) and 71.5 (50 mg/mL) versus 9.6 for placebo over 6 months, with no adverse events [4]. This combination — 5-ALA plus GHK, not pure GHK-Cu — is the strongest controlled human signal in the literature. Earlier, peptide-copper complexes stimulated follicle activity in C3H mice [9]. The controlled regrowth evidence is genuine but rests on a combination formulation, which is the honest boundary on the claim that a copper peptide regrows hair. ## Do copper peptides stimulate hair growth? A 6-month trial of 45 men with androgenetic alopecia using a 5-ALA plus GHK complex increased hair count significantly versus placebo [4], and peptide-copper complexes stimulated follicle activity in C3H mice [9]. A 2026 review attributes the effect to VEGF-driven angiogenesis and follicular extracellular-matrix turnover [5]. The stimulation is documented in both a controlled human trial and an animal model, with a coherent angiogenic mechanism. ## Does copper peptide work for hair growth? A 2026 review reports GHK-Cu increases VEGF production in dermal fibroblasts, stimulates microvascular angiogenesis and collagen/glycosaminoglycan synthesis, and promotes follicular extracellular-matrix turnover, citing the 45-patient androgenetic-alopecia trial as foundational peptide hair-loss evidence [5]. The mechanistic case is consistent — angiogenesis and matrix turnover support the follicle — and is backed by one controlled human trial of a combination formulation [4] and a founding mouse study [9]. ## How long does GHK-Cu take to regrow hair? The controlled human evidence comes from a 6-month topical trial that measured significant hair-count gains at study end [4]. Community PAA-level answers cite meaningful regrowth around 3 months, but the research does not standardize a timeline, and the trial reported its outcome at the 6-month endpoint rather than tracking a defined onset. No timeline here should be read as a usage recommendation; it describes when a study measured its result. ## Is copper a DHT blocker? Copper-peptide hair research describes a non-androgenic mechanism rather than DHT blockade. A 2024 microemulsion study driving follicles into anagen reported no change in testosterone or estradiol, indicating GHK-Cu acts via angiogenesis and follicle biology rather than by blocking dihydrotestosterone [5]. This distinguishes copper peptides mechanistically from 5-alpha-reductase inhibitors: the documented pathway is VEGF, microvascular angiogenesis and follicular matrix turnover, not hormonal suppression. --- A 1970s field guide to the GHK-Cu copper-peptide literature — five decades of skin, hair, wound-repair and gene-expression findings surveyed and pinned to their sources, with no clinic at the trailhead and nothing here to sell.